Quick answer: Neurology prior authorization automation software is usually worth it when your monthly PA volume is high, because it pays back faster than additional staff — clearing the routine majority of requests while your coordinators handle exceptions. The decision comes down to a comparison: the loaded cost of hiring and retaining PA staff against the cost of automation plus the revenue it protects from denials and expired authorizations. For most mid-to-large neurology practices, the math favors automating the volume and redeploying staff to the work that needs judgment.
The real question isn't software vs. staff — it's what each is good at
The build-vs-buy framing is a little misleading, because the honest end state uses both. The question a neurology COO or CFO is actually deciding is which work belongs to people and which belongs to software.
Hiring more prior authorization coordinators scales linearly: every increment of volume needs another fraction of a person, and that person needs recruiting, training, benefits, and a desk. Automation scales differently — once it's integrated, marginal volume is nearly free, but it doesn't handle everything. Peer-to-peer reviews, appeals strategy, and clinical judgment calls still need a human.
So the comparison isn't "replace the team with a robot." It's "should the next unit of PA capacity come from a new hire or from software, given that some of the work will always be human?" Framed that way, the answer usually depends on one variable: how much repeatable, rules-based volume you're running.
What more staff actually costs
Adding headcount is the familiar option, so its costs feel smaller than they are. A full accounting includes more than salary.
A prior authorization coordinator carries a fully loaded cost — salary plus benefits, payroll taxes, and overhead — that runs well above the base wage. On top of that sits turnover: PA work is repetitive and burnout-prone, and the 2024 AMA prior authorization survey found 89% of physicians say prior authorization contributes to burnout — a burden that lands just as hard on the staff doing the submissions. Every departure means re-recruiting and re-training, and a new coordinator takes months to learn your payer mix.
There's also a ceiling problem. The same survey found practices average 39 prior authorizations per physician per week, eating about 13 hours of staff and physician time. In neurology, where the procedure mix skews auth-heavy, that load is higher — and you can't always hire fast enough to keep pace with a growing schedule. Staffing solves volume slowly and expensively, and the solution walks out the door periodically.
What automation costs — including the parts vendors skip
Automation has its own cost lines, and a credible comparison includes the ones that don't show up in a sales deck.
- Software cost, typically priced against your volume — the line you'll weigh against a salary.
- Implementation and integration, connecting to your EHR through HL7 or FHIR and running a parallel-validation period, usually 30–60 days of calendar time and some staff attention.
- Payer-mix coverage gaps. No platform covers every payer equally; ask which of your top ten payers it handles touchlessly today, and discount for the ones it doesn't.
- Exception staffing. You still need someone owning the flagged queue — you're shrinking the PA function, not deleting it.
- A tuning quarter. Month one runs below steady state while the system learns your payers; model year-one savings on roughly ten months, not twelve.
A comparison that includes these survives scrutiny from a skeptical partner group. One that promises 100% automation and instant savings dies at the first hard question.
How the math usually breaks down
The decision turns on volume, and a rough model shows why. Take the labor side first: the 2024 CAQH Index prices a manual prior authorization at roughly $11 in provider labor versus about half that fully electronic — and in specialty workflows the cumulative touch time (data gathering, portal entry, repeated status checks) commonly runs 20–45 minutes per auth.
Multiply your monthly manual auth count by that touch time and your loaded staff cost, and you have the number automation is trying to beat. For a practice running hundreds of auths a month, the labor line alone often clears the software cost several times over, before counting a single prevented denial. For a low-volume practice, the gap narrows, and hiring (or outsourcing piecemeal) may make more sense.
The honest discipline here is to model the touchless rate at 75–85%, never 100% — real neurology volume includes peer-to-peers and judgment calls that should route to humans. Present labor savings as the floor, and treat denial prevention and faster throughput as upside you'll track after go-live rather than promise up front.
The revenue you're losing right now
The staffing comparison undercounts automation's value because it ignores the revenue leaking out of a manual process. In neurology, that leak is real and specific.
Botox authorizations expire when no one tracks the window, turning a covered injection into a write-off. Infusion claims get denied for missing NDC or J-code detail. High-cost drug auths — CGRP biologics, MS therapies — get denied on first pass because the step-therapy documentation was incomplete. Each of these is preventable, and each one is money a fully staffed manual process still loses because people get busy and authorizations slip.
Automation closes these gaps not because software is smarter than your coordinators, but because it doesn't forget, doesn't get pulled onto a phone call mid-task, and doesn't leave for a better job. When you compare against hiring, factor in the denials and write-offs you'll keep eating with a manual process no matter how well-staffed it is.
The end state: a smaller, sharper PA team
The realistic outcome of automating isn't an empty department — it's a redeployed one, and saying so up front matters for how your team receives the change.
What happens in practice: coordinators stop keying chart data into portals and shift to exception handling — peer-to-peer scheduling, appeals on high-dollar denials, and the genuinely ambiguous cases. Their payer knowledge, which automation can't replicate, gets applied where it actually moves the needle. This is where a platform like Honey Health fits the decision: its Prior Authorization agent handles the routine volume and runs alongside its eligibility and referral intake agents, so the recovered hours don't get re-absorbed coordinating between systems.
The financial value is the same as hiring — it's capacity you'd otherwise pay for — but you get it without the recruiting cycle, the turnover, and the linear cost curve. For most neurology practices with real PA volume, that's why the buy decision wins.
Frequently asked questions
Is neurology prior authorization automation software worth it?
For most mid-to-large neurology practices, yes — the return scales with PA volume, and high-volume practices typically see automation pay back faster than hiring. It clears routine imaging, drug, and procedure auths while staff handle exceptions. Low-volume practices should model the return against their actual monthly auth count before deciding.
Is it cheaper to automate prior authorization or hire more staff?
It depends on volume. Hiring scales linearly with cost — salary, benefits, turnover, and training — while automation has higher upfront integration cost but near-zero marginal cost per auth. For practices running hundreds of auths a month, automation usually wins on labor alone; for low volume, the gap narrows.
Does prior authorization automation eliminate jobs?
Usually not. It removes repetitive data-gathering and status-chasing, so coordinators shift to peer-to-peer scheduling, appeals, and judgment calls. Most neurology practices redeploy recovered hours rather than cut headcount, keeping experienced staff whose payer knowledge the software can't replace.
How quickly does prior authorization automation pay for itself?
Practices with meaningful volume typically reach payback within two to three quarters on labor savings alone, with denial prevention and faster throughput following. Model year-one savings on about ten months of steady-state performance to account for the tuning quarter after go-live.
What hidden costs should we include in the comparison?
Beyond software pricing, include implementation and EHR integration, a 30–60 day parallel-validation period, payer-mix coverage gaps, exception-queue staffing, and a tuning quarter where the system runs below steady state. A comparison that includes these is far more credible than one promising instant, total automation.
What's the biggest mistake practices make with this decision?
Comparing software cost only against salary, while ignoring the revenue a manual process leaks — expired Botox authorizations, miscoded infusions, and denied drug auths. A fully staffed manual process still loses that money; factoring it in often changes the answer.
